Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy
ISRN Pharmacology · 2011
DOI: 10.5402/2011/430549 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Pharmacology, 2011. Verfasst von Wawaimuli Arozal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima …. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Promotion and Mutual Aid Corporation for Private Schools of Japan.
Abstract (Originalsprache)
Anthracyclines, most powerful anticancer agents, suffer from their cardiotoxic effects, which may be due to the induction of oxidative stress. Carvedilol, a third-generation, nonselective β -adrenoreceptor antagonist, possesses both reactive oxygen species (ROS) scavenging and ROS suppressive effects. It showed protective effects against daunorubicin- (DNR-) induced cardiac toxicity by reducing oxidative stress and apoptosis. This study therefore was designed to examine the effects of carvedilol on DNR-induced cardiomyopathic rats, focused on the changes of left ventricular function, cardiac fibrosis, and hypertrophy. Carvedilol increased survival rate, prevented systolic and diastolic dysfunction, and attenuated myocardial fibrosis and hypertrophy. DNR alone treated rats showed upregulated myocardial expression of ANP, PKC- α , OPN, and TGF- β 1 and downregulation of GATA-4 in comparison with control, and treatment with carvedilol significantly reversed these changes. The results of the present study add the available evidences on the cardioprotection by carvedilol when associated with anthracyclines and explain the mechanisms underlying the benefits of their coadministration.
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-Ku, Niigata City 956-8603, Japan.
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Promotion and Mutual Aid Corporation for Private Schools of Japan
Zitieren
APA
Arozal, W., Sari, F. R., Watanabe, K., Arumugam, S., Veeraveedu, P. T., Ma, M., Thandavarayan, R. A., Sukumaran, V., Lakshmanan, A. P., Kobayashi, Y., Mito, S., Soetikno, V., & Suzuki, K. (2011). Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology. https://doi.org/10.5402/2011/430549
Vancouver
Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, Ma M, et al. Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology. 2011. doi:10.5402/2011/430549
BibTeX
@article{Arozal2011,
author = {Arozal, Wawaimuli and Sari, Flori R and Watanabe, Kenichi and Arumugam, Somasundaram and Veeraveedu, Punniyakoti T and Ma, Meilei and Thandavarayan, Rajarajan A and Sukumaran, Vijayakumar and Lakshmanan, Arun Prasath and Kobayashi, Yoshiyasu and Mito, Sayaka and Soetikno, Vivian and Suzuki, Kenji},
title = {Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy},
journal = {ISRN Pharmacology},
year = {2011},
doi = {10.5402/2011/430549}
}
EUVIMED